Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring
- 1 June 2012
- journal article
- review article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (6), 2806-2813
- https://doi.org/10.1128/aac.05900-11
Abstract
Posaconazole has become an important part of the antifungal armamentarium in the prophylaxis and salvage treatment of invasive fungal infections (IFIs). Structurally related to itraconazole, posaconazole displays low oral bioavailability due to poor solubility, with significant drug interactions and gastrointestinal disease also contributing to the generally low posaconazole plasma concentrations observed in patients. While therapeutic drug monitoring (TDM) of plasma concentrations is widely accepted for other triazole antifungal agents such as voriconazole, the utility of TDM for posaconazole is controversial due to debate over the relationship between posaconazole exposure in plasma and clinical response to therapy. This review examines the available evidence for a relationship between plasma concentration and clinical efficacy for posaconazole, as well as evaluating the utility of TDM and providing provisional target concentrations for posaconazole therapy. Increasing evidence supports an exposure-response relationship for plasma posaconazole concentrations for prophylaxis and treatment of IFIs; a clear relationship has not been identified between posaconazole concentration and toxicity. Intracellular and intrapulmonary concentrations have been studied for posaconazole but have not been correlated to clinical outcomes. In view of the high mortality and cost associated with the treatment of IFIs, increasing evidence of an exposure-response relationship for posaconazole efficacy in the prevention and treatment of IFIs, and the common finding of low posaconazole concentrations in patients, TDM for posaconazole is likely to be of significant clinical utility. In patients with subtherapeutic posaconazole concentrations, increased dose frequency, administration with high-fat meals, and withdrawal of interacting medications from therapy are useful strategies to improve systemic absorption.Keywords
This publication has 58 references indexed in Scilit:
- Relevance of Timing for Determination of Posaconazole Plasma ConcentrationsAntimicrobial Agents and Chemotherapy, 2011
- Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal TherapyThe Journal of Infectious Diseases, 2011
- Clinical pharmacodynamics and pharmacokinetics of the antifungal extended‐spectrum triazole posaconazole: an overviewBritish Journal of Clinical Pharmacology, 2010
- Therapeutic Drug Monitoring of Posaconazole in Hematology Patients: Experience with a New High-Performance Liquid Chromatography-Based MethodAntimicrobial Agents and Chemotherapy, 2010
- Pharmacokinetics of Posaconazole Administered Orally or by Nasogastric Tube in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2009
- Simultaneous Determination of Voriconazole and Posaconazole Concentrations in Human Plasma by High-Performance Liquid ChromatographyAntimicrobial Agents and Chemotherapy, 2009
- Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory ExperienceAntimicrobial Agents and Chemotherapy, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and YeastsAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2006